tailieunhanh - báo cáo khoa học: "Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma | Wang et al. Journal of Hematology Oncology 2010 3 30 http content 3 1 30 JOURNAL OF HEMATOLOGY ONCOLOGY CASE REPORT Open Access Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma U A s 1 2 1 3 2 4 111 1 Wang Wen-Yu Shi Zhi-Yuan vvu Mariana Varna Ai-Hua Wang LI Zhou LI Chen Zhi-Xiang Shen He Lu2 4 Wei-Li Zhao1 2 Anne Janin2 4 Abstract Mantle cell lymphoma MCL is a rare and aggressive type of B-cell non-Hodgkin s lymphoma. Patients become progressively refractory to conventional chemotherapy and their prognosis is poor. However a 38 remission rate has been recently reported in refractory MCL treated with temsirolimus a mTOR inhibitor. Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after tem-sirolimus treatment and a progression-free survival of 10 months. In this case lymph node biopsies were performed before and six months after temsirolimus therapy. Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest but did not induce any change in the number of apoptotic tumor cells. Apart from this cytostatic effect temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and ofVEGF expression. Moreover numerous patchy well-limited fibrotic areas compatible with post-necrotic tissue repair were found after 6-month temsirolimus therapy. Thus temsiroli-mus reduced tumor burden through associated cytostatic and anti-angiogenic effects. This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy. Background Mantle cell lymphoma MCL is an aggressive B-cell non-Hodgkin s lymphoma NHL representing about 6 of NHL cases. T 11 14 q13 q32 chromosomal translocation one of the most important cytogenetic abnormalities of MCL juxtaposes genes of cyclin D1 and of immunoglobulin heavy chain inducing .